Boston Scientific announces board member Charles Dockendorff's departure

Boston Scientific Corporation (NYSE: BSX) announced today that Charles J. Dockendorff will not seek re-election to its Board of Directors at the upcoming 2025 Annual Meeting of Stockholders. Dockendorff, who has been a board member since April 2015, currently serves on the Audit Committee and the Risk Committee. According to the company's SEC filing, Dockendorff's decision to leave the board is not due to any disagreements with the company's operations, policies, or practices. The company has demonstrated strong performance, with revenue growth of 17.6% in the last twelve months.

Dockendorff's tenure on the board will continue until the 2025 Annual Meeting. Boston Scientific's Board and Nominating and Governance Committee are evaluating the board's size and composition to decide if new directors should be added following Dockendorff's departure.

You May Also Be Interested In

• Avidbank closes $30M subordinated debt offering at 7% fixed rate
• FibroBiologics regains Nasdaq compliance for bid price rule
• SEC clears VerifyMe and OpenWorld merger registration statement